Código 300190 (Harmonized System 2012 by 6 digits)
2023: US$60.4M, Total Trade Exchange
2023: US$18.3M, International Sales
2023: US$42.1M, International Purchases
In 2023, the trade exchange (includes international purchases and sales) of Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C was US$60.4M.
In 2023, the states with the most international sales in Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C were Ciudad de México (US$6.5M) and Estado de México (US$75).
The states with the most international purchases in 2023 were Jalisco (US$19.9M), Ciudad de México (US$9.34M), Guanajuato (US$2.96M), Baja California (US$1.24M), and Nuevo León (US$108k).
In 2023, the main commercial destinations of Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C were Spain (US$5.75M), Peru (US$251k), Colombia (US$145k), Chile (US$117k), and United States (US$96.9k).
The main commercial origins of Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C in 2023 were China (US$16M), United States (US$9.66M), Spain (US$2.83M), Costa Rica (US$2.47M), and Brazil (US$1.43M).
In the global context, the main exporting countries of Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C in 2022 were China (US$1.24B), United States (US$772M), and France (US$744M). In the same year, the main importing countries of Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C were France (US$1.14B), Singapore (US$657M), and United States (US$415M).
US$60.4M, Total Trade Exchange (2023)
In 2023, the total trade exchange of Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C in Mexico (including international purchases and sales) was US$60.4M.
The visualizations show the net balance of Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
November, 2024
In November 2024, international sales of Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C were US$133k, while international purchases reached US$1.9M. The above results in a trade balance of -US$1.77M.
2024-Q4: US$83.2k, International Sales
The visualization shows the quarterly concentration of international sales of Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C at state level.
In the fourth quarter of 2024, international sales were US$83.2k, being the states with the most sales Ciudad de México (US$83.2k).
Ciudad de México: US$6.5M, State with the Most International Sales (2023)
Spain: US$5.75M, Main commercial destination (2023)
In 2023, the states with the highest international sales in Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C were Ciudad de México (US$6.5M) and Estado de México (US$75).
In 2023, the countries with the most international purchases from Mexico were Spain (US$5.75M), Peru (US$251k), Colombia (US$145k), Chile (US$117k), and United States (US$96.9k).
Jalisco: US$19.9M, State with the Most International Purchases (2023)
China: US$16M, Main Commercial Origin (2023)
In 2023, the states with the highest international in Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C were Jalisco (US$19.9M), Ciudad de México (US$9.34M), Guanajuato (US$2.96M), Baja California (US$1.24M), and Nuevo León (US$108k).
The countries with the most international sales to Mexico in 2023 were China (US$16M), United States (US$9.66M), Spain (US$2.83M), Costa Rica (US$2.47M), and Brazil (US$1.43M).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C were China (US$1.24B), United States (US$772M), and France (US$744M). In the same year, the main importing countries for Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C were France (US$1.14B), Singapore (US$657M), and United States (US$415M).